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Abstract
Background: Increasing resistance to standard antibiotics has been demonstrated in CF patients colonised by Pseudomonas
aeruginosa. The antibiotic Fosfomycin has a unique mode of action against this organism, and may protect against aminoglycoside
mediated renal and ototoxic effects. However, there is little published experience of this drug in IV form, and it is not licensed
for use in the UK. Methods: In combination with other antibiotics, we used Fosfomycin to treat 30 pulmonary exacerbations in
15 adult CF patients colonised by P. aeruginosa, mainly multiresistant strains. All patients gave informed consent. We cultured
sputum prior to treatment and measured spirometry, renal function, and symptoms before and after treatment, and recorded any
side effects. Results: One patient developed nausea and Fosfomycin treatment was withdrawn. The remaining patients showed
clinical resolution of their chest exacerbations (mean FEV1% predicted: pre 41.1 vs. post 49.4, P-0.001). Although there was a
statistical increase in plasma urea (pre 3.9 mmolyl vs. post 4.3, P-0.03), this was still within the normal range. Plasma creatinine
was unchanged. Conclusions: This study shows that IV Fosfomycin is well tolerated by adult patients with CF and can be useful
in the treatment of those colonised with multiresistant P. aeruginosa.
 2003 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Most adult patients with cystic fibrosis (CF) are
colonised with Pseudomonas aeruginosa, which in some
studies has been shown to confer a poor prognosis w1x.
In many of these patients, pulmonary exacerbations
require treatment with intravenous combinations of
antipseudomonal antibiotics, including aminoglycosides
that have been shown to cause auditory w2x and renal
w3x toxicity. Furthermore, in cystic fibrosis patients,
isolates of P. aeruginosa are becoming increasingly
resistant to conventional antipseudomonal antibiotics w4x
and in our unit of over 140 adult CF patients where
80% are colonised by this organism, 75% are now
multiresistant.
We have therefore looked for other antibiotics that
possess antipseudomonal activity. One such antibiotic is
fosfomycin (1,2-epoxypropylphosphonic acid) originally
isolated in 1969 from Streptomyces fradiae and other
Streptomyces species w5x but now produced synthetically.
*Corresponding author.
Fosfomycin is a unique broad-spectrum bactericidal
antibiotic w6x chemically unrelated to any other known
antimicrobial agent. It is available in oral formulations
as fosfomycin calcium or fosfomycin trometamol, and
in intravenous formulation as fosfomycin disodium.
Following intravenous administration of the disodium
salt 80–95% of the drug is excreted unchanged in the
urine by glomerular filtration within 24 h, the serum
half-life is 1.5–2 h, the antibiotic is not bound to serum
proteins and its volume of distribution is large w7,8x. Its
diffusion into tissues and body fluids including cerebro-
spinal fluid is good w9x; the concentration of fosfomycin
in lung tissue can be up to 50% of serum levels 1–2 h
after administration w10x. It is taken up actively into
bacterial cells through two nutrient transport systems
present in various bacteria (including P. aeruginosa),
and inhibits the initial step in cell wall synthesis w11x.
However, in vitro susceptibility testing for fosfomycin
against P. aeruginosa requires the presence of glucose-
6-phosphate, which is not routinely incorporated into
standard sensitivity testing agars. Thus without this,
sensitive strains may appear resistant w12x. Furthermore,
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Table 1
Sensitivity patterns of the three most common organisms found in sputum culture and use of intravenous antibiotics used during the study
IV antibiotics (dose) % courses % sensitivity of organisms
Pseudomonas aeruginosa Burkholderia cepacia Staphylococcus aureus
S I R S I R S I R
Ceftazidime 3 g tds 19 24.6 8.2 67.2 0 100 0 33.3 0 66.7
Colomycin 2 MU tds 32 100 0 0 0 0 100 0 0 100
Tobramycin 140–160 mg tds 32 83.6 4.9 11.5 0 0 100 100 0 0
Meropenem 1 g tds 32 31.1 8.2 60.7 0 0 100 100 0 0
Aztreonam 2 g tds 0 23 8.2 68.8 0 0 100 0 0 100
Cotrimoxazole 1.44 g bd 6 0 0 100 0 100 0 100 0 0
Imipenem 500 mg tds 0 21.3 4.9 73.8 0 0 100 100 0 0
Piperacillin 4 g tds 0 27.9 6.6 65.5 0 0 100 0 0 100
Gentamicin 140–160 mg tds 0 23 9.8 67.2 0 0 100 100 0 0
Ciprofloxacin 400 mg bd 0 42.6 8.2 49.2 0 0 100 0 0 100
Key: Sssensitive; Isintermediate sensitivity; Rsresistant.
it has been suggested that fosfomycin may protect
against aminoglycoside nephro—w13,14x and oto—tox-
icity w15,16x.
Thus it would seem that fosfomycin might be an
effective antibiotic, as part of combination intravenous
therapy, for the treatment of pseudomonas pulmonary
exacerbations in CF, with the added benefit of conferring
renal and auditory protection from concomitant aminog-
lycoside use. However, we are not aware of any studies
that have used this antibiotic in CF patients. We have
therefore examined the efficacy and side effects of
fosfomycin used as part of combination therapy over a
5-year period in a group of adult CF patients with
multiresistant P. aeruginosa infections.
2. Patients and methods
Because fosfomycin is not licensed for use in the UK,
we have only given it to patients with pulmonary
exacerbations where there was pathogen multiresistance
or patient intolerance to standard antipseudomonal anti-
biotics, or if patients had developed dose related side-
effects (such as renal and oto-toxicity with
aminoglycosides). Fosfomycin was prescribed at a dose
of 5 g tds and imported from Germany for these
individuals on a named patient basis. Overall, 15 patients
wmean age 23 years (range 18–37 years), 9 femalex
received fosfomycin and they formed the study
population.
The number and length of courses of intravenous
fosfomycin, the dose prescribed, other intravenous anti-
biotics co-administered, pre- and post-treatment spirom-
etry, pre- and post-treatment serum urea and creatinine,
bacteria cultured from sputum and their sensitivities w17x
and any reported side effects were recorded.
2.1. Statistics
Results are expressed as mean plus (S.D.) or (range)
as appropriate. Comparisons were made using paired t-
tests. A P value of -0.05 was considered significant.
3. Results
A total of 30 courses of fosfomycin were prescribed
wmean 2 courses per patient, (range 1–3), course length
mean 16.6 days (range 7—36)x; in combination with
one other intravenous antibiotic in 20 courses (67%)
and with two others in 10 courses (33%) (Table 1).
Overall, a total of 499 days of fosfomycin therapy were
given.
3.1. Spirometry
There was a significant increase in spirometry after
fosfomycin combination treatment wFEV % predicted:1
pre-treatment mean 41.1 wrange 14–96), post-treatment
mean 49.4 (range 16–97); P-0.001x (Fig. 1).
3.2. Renal function
Pre- and post-treatment renal function data were
available for 24 courses of fosfomycin. There was no
change in serum creatinine (pre-treatment: mean 85
umolyl (S.D. 27.6), post-treatment: mean 78.1 mmolyl
(S.D. 14.8): (PsNS) (Fig. 2). Whilst there was a
statistical increase in urea following treatment (pre
treatment: mean 3.9 mmolyl (S.D. 1.7), post-treatment
mean: 4.3 mmolyl (S.D. 1.6) (P-0.03), this was not
clinically significant (Fig. 3).
3.3. Sputum pathogens
All patients were infected with multiresistant P. aeru-
ginosa (61 isolates). In addition, 3 patients were co-
infected with Staphylococcus aureus, 1 with
Haemophilus influenzae, 1 with Proteus spp., and 3
with Burkholderia cepacia. Sensitivity patterns of the
three most common organisms found in sputum culture
and use of other intravenous antibiotics used during the
study are given in Table 1. Sensitivity patterns to
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Fig. 1. Change in spirometry with fosfomycin treatment.
Fig. 2. Change in serum creatinine with fosfomycin treatment. The broken lines indicate the limits of the normal range.
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Fig. 3. Change in serum urea with fosfomycin treatment. The broken lines indicate the limits of the normal range.
fosfomycin were not included because of the difficulty
in obtaining therapeutically meaningful results, as illus-
trated earlier. Nevertheless, 8 of the 15 patients (53%)
had strains sensitive to fosfomycin using this method.
3.4. Side effects
One patient experienced nausea during combination
treatment with fosfomycin, and the drug was withdrawn.
4. Discussion
Patients with cystic fibrosis who are infected with P.
aeruginosa will require repeated courses of intravenous
antipseudomonal antibiotics for pulmonary exacerba-
tions. This repeated use of a limited selection of antibi-
otics encourages the development of resistance, and
many adult patients with CF now harbour multiresistant
P. aeruginosa strains w4x. Furthermore, repeated use of
the same antibiotics results in patient intolerance and
increased side effects. Thus, in such patients fosfomycin
may be useful when co-administered with other antibi-
otics for a number of reasons.
Firstly, the vigorous inflammatory response in the CF
lung encourages P. aeruginosa to form microcolonies
surrounded by negatively charged polysaccharides (the
biofilm or glycocalyx) w18,19x. This biofilm allows the
persistence of the organism in the face of specific
antibodies and antibiotics w20x. However, in vitro fos-
fomycin does not react with the negatively charged
glycocalyx and in vivo may therefore be able to pene-
trate the biofilm w21x.
Secondly, in vitro a synergistic effect has been dem-
onstrated in combination with ofloxacin against P. aeru-
ginosa growing in a biofilm w22x, and with ciprofloxacin
against P. aeruginosa isolates from CF patients w23x.
This may be because fosfomycin acts on different
synthetic pathways, demonstrating synergy against P.
aeruginosa when used in combination with a wide
variety of other antibiotics including b-lactams, aminog-
lycosides, macrolides and tetracyclines w24–29x.
Thirdly, because fosfomycin acts on synthetic path-
ways unaffected by other agents, the potential for the
development of cross-resistance with other classes of
antibiotics is reduced w30x.
Fourthly, when co-administered, fosfomycin has been
shown to reduce aminoglycoside-associated nephrotox-
icity by protecting lysosomal membrane integrity
w13,31x. A similar mechanism may account for protec-
tion against aminoglycoside-related ototoxicity w15,16x.
Finally, fosfomycin has an excellent side-effect pro-
file. Indeed, the main side effects are gastrointestinal
(nausea, vomiting, diarrhoea and a transient increase in
serum transaminase levels) thought to be most common
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with the oral preparations, occurring in 2–8% of cases
w32,33x. Mayama et al. reported pseudomembraneous
colitis and melaena in only 2 out of 35481 cases, again
with oral formulations of fosfomycin w34x. There are no
specific reports in the literature of side effects with the
IV preparation.
Despite all these potential advantages of fosfomycin,
to the authors’ knowledge it has not previously been
used in combination with other intravenous antibiotics
in the management of pulmonary exacerbations in CF
patients in the UK. Our study of 499 patient days of
fosfomycin use has demonstrated that significant
improvements in spirometry were obtained without com-
promising renal function and with minimal side effects.
Only one patient reported nausea with fosfomycin,
which had to be discontinued. Meaningful sensitivity
profiles to fosfomycin were not reported in this study,
since the media used routinely for in-vitro testing do
not include glucose-6-phosphate and sensitive strains
may therefore appear resistant w12x. Even using this
method, however, over half our patients harboured Pseu-
domonas strains sensitive to fosfomycin. Other workers
have found similar patterns w29x. Furthermore, Wolter et
al. found no correlation between clinical outcome para-
meters and susceptibility of P. aeruginosa colonies to
the antibiotics used in a group of adult CF patients w35x.
Thus, in our experience, fosfomycin given intrave-
nously in combination with other antibiotics for pul-
monary exacerbations in CF patients colonised by
multiresistant P. aeruginosa resulted in clinical improve-
ment with a low side effect profile. We recommend its
use to other CF centres where multiresistant strains are
common.
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